期刊文献+

Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report

下载PDF
导出
摘要 BACKGROUND Pancreatic mucinous cystadenocarcinoma(MCAC)is a rare malignancy with a poor prognosis when it presents metastases at diagnosis.Due to its very low incidence,there are no clear recommendations for the treatment of advanced disease.Olaparib(an oral PARP inhibitor)has been approved for the maintenance treatment of patients with metastatic pancreatic adenocarcinoma harbouring germline BRCA1/2 mutations.Herein,we report the first case of a germline BRCA1 mutated unresectable MCAC which was effectively treated with olaparib.CASE SUMMARY A 41-year-old woman,without personal or family history of cancer,was diagnosed with ovarian and peritoneal metastases of MCAC.She underwent 12 cycles of gemcitabine plus oxaliplatin(GEMOX)obtaining a partial response and allowing radical surgery.One year later,local recurrence was documented,and other 12 cycles of GEMOX were administered obtaining a complete response.Seven years later,another local recurrence,not amenable to surgical resection,was diagnosed.She started FOLFIRINOX(oxaliplatin,irinotecan,leucovorin and fluorouracil),obtaining a partial response after 8 cycles.Given the excellent response to platinum-based chemotherapy,BRCA testing was performed,and a BRCA1 germline mutation was detected.She was switched to maintenance olaparib due to chemotherapy-related toxicities and achieved an almost complete metabolic response,with a reduction in the diameter of the lesion,after three months of therapy.CONCLUSION The current case suggests the beneficial effect of olaparib in BRCA mutated MCAC.However,further studies are required.
出处 《World Journal of Gastrointestinal Oncology》 SCIE CAS 2020年第12期1456-1463,共8页 世界胃肠肿瘤学杂志(英文版)(电子版)
  • 相关文献

参考文献1

二级参考文献110

  • 1FerlayJ, Shin HR, Bray F, Forman D, Mathers C etal. Estimatesofworldwide burden of cancer in 2008: GLOBOCAN 2008. IntJ Cancer 2010; 127: 2893-917.
  • 2Lee J, Demissie K, Lu SE, Rhoads GG. Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea. Cancer Control 2007; 14: 78-85.
  • 3Jemal A, Bray F, Center MM, Ferlay J, Ward E etal. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
  • 4Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992; 89: 3367-71.
  • 5Eeles RA. Genetic predisposition to prostate cancer. Prostate Cancer Prostatic Dis 1999; 2: 9-15.
  • 6Edwards SM, Eeles RA. Unravelling the genetics of prostate cancer. Am J Med GenetC Semin Med Genet 2004; 129C: 65-73.
  • 7Lichtenstein P, Holm NV, Verkasalo PK, lIiadou A, Kaprio J et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78-85.
  • 8Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007; 39: 645-9.
  • 9AI Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison Jet al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet 2009; 41: 1058-60.
  • 10Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006; 38: 652-8.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部